Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.

doi:10.1093/carcin/bgab026

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.

Carcinogenesis - 28 May 2021

Aglago Elom K, Schalkwijk Casper G, Freisling Heinz, Fedirko Veronika, Hughes David J, Jiao Li, Dahm Christina C, Olsen Anja, Tjønneland Anne, Katzke Verena, Johnson Theron, Schulze Matthias B, Aleksandrova Krasimira, Masala Giovanna, Sieri Sabina, Simeon Vittorio, Tumino Rosario, Macciotta Alessandra, Bueno-de-Mesquita Bas, Skeie Guri, Gram Inger Torhild, Sandanger Torkjel, Jakszyn Paula, Sánchez Maria-Jose, Amiano Pilar, Colorado-Yohar Sandra M, Gurrea Aurelio Barricarte, Perez-Cornago Aurora, Mayén Ana-Lucia, Weiderpass Elisabete, Gunter Marc J, Heath Alicia K, Jenab Mazda

Abstract excerpt

Advanced glycation end-products (AGEs) are a heterogeneous group of compounds formed by the non-enzymatic reaction between amino acids and reducing sugars, or dicarbonyls as intermediate compounds. Experimental studies suggest that AGEs may promote colorectal cancer, but prospective epidemiologic studies are inconclusive. We conducted a case-control study nested within a large European cohort. Plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatography, Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Glycation End Products, Advanced

Share to Tandem Mass Spectrometry

Source

Open in PubMed Open full text

Identifiers

PMID: 33780524
DOI: 10.1093/carcin/bgab026
PMCID: PMC8162627

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.PMID 33780524Read ↗

The contribution of dietary advanced glycation end-products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study.Semantic proximity Read ↗

Protein Arginine Deiminase 4 Antagonizes Methylglyoxal-induced Histone GlycationSemantic proximity Read ↗

A genome-wide systems analysis reveals strong link between colorectal cancer and trimethylamine N-oxide (TMAO), a gut microbial metabolite of dietary meat and fatSemantic proximity Read ↗

Cys34 Adductomics Links Colorectal Cancer with the Gut Microbiota and Redox BiologySemantic proximity Read ↗

Free advanced glycation end product distribution in blood components and the effect of genetic polymorphisms.Semantic proximity Read ↗

Glyoxal induces DNA-Protein Crosslinking in CellsSemantic proximity Read ↗

Higher dietary advanced glycation products intake is associated with increased risk of dementia, independent from genetic predisposition.Semantic proximity Read ↗

Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and MortalitySemantic proximity Read ↗

Methylglyoxal-Mediated Stress Correlates with High Metabolic Activity and Promotes Tumor Growth in Colorectal CancerSemantic proximity Read ↗

Novel Proteomic Strategy Reveal Combined α<sub>1</sub> Antitrypsin and Cathepsin D as Biomarkers for Colorectal Cancer Early ScreeningSemantic proximity Read ↗

A Cyclic Arginine Adduct Eclipses Carboxymethylation as the Primary Glyoxal-Derived Advanced Glycation End-ProductSemantic proximity Read ↗

Soluble Receptor for Advanced Glycation End-products (sRAGE) and Colorectal Cancer Risk: A Case-Control Study Nested within a European Prospective Cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.